Skip to content
drillr.ai
Sign up

REPL

Replimune Group, Inc.

NASDAQ · Healthcare · Biotechnology · US

$15.04
−1.64%
Ask drillr

  • Aug 14, 2026, 12:00 UTC

    Replimune Group announced the appointment of Michelle DiNapoli as Chief Commercial Officer.

    Source:

  • Aug 14, 2026, 00:00 UTC

    Replimune Group reported a net loss of $69.8 million for Q1 2027, compared to a net loss of $86.7 million in Q1 2026, with diluted EPS of -$0.72.

  • Aug 11, 2026, 05:21 UTC

    Replimune Group's stock gapped up at market open on Monday after JPMorgan Chase raised its price target from $17.00 to $20.00, with the stock opening at $12.64 after closing at $12.06.

    Source:

  • Aug 11, 2026, 00:00 UTC

    A securities class action lawsuit was filed against Replimune Group, Inc., alleging materially false and misleading statements regarding its Biologics License Application for RP1 and related study deficiencies.

    Source:

  • Aug 10, 2026, 12:00 UTC

    Replimune Group priced an underwritten offering of common stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds.

    Source:

  • Aug 6, 2026, 19:59 UTC

    The U.S. Food and Drug Administration granted accelerated approval to Replimune's melanoma treatment RP1, to be marketed as Tudriqev, after the drug had been rejected twice previously.

    Source:

  • Jul 30, 2026, 22:15 UTC

    Replimune announced the outcome of the FDA advisory committee meeting discussing its BLA resubmission for RP1 in advanced melanoma.

    Source:

  • Jul 28, 2026, 13:39 UTC

    The FDA reiterated concerns that Replimmune lacks adequate data to support approval of its skin cancer treatment RP1, ahead of an advisory committee meeting.

    Source:

  • Jun 30, 2026, 14:09 UTC

    Replimune Group, Inc. faces a pivotal FDA Advisory Committee meeting for its RP1 therapy after two prior rejections, with a final FDA approval decision expected on August 2, 2026.

    Source:

  • Jun 29, 2026, 12:00 UTC

    Replimune Group reported financial results for the fiscal fourth quarter and year ended March 31, 2026.

    Source:

  • Jun 26, 2026, 12:00 UTC

    The FDA accepted for review Replimune's resubmitted Biologics License Application for RP1 in combination with nivolumab for advanced melanoma.

    Source:

  • Jun 1, 2026, 18:06 UTC

    Replimune aligned with the FDA on plans to resubmit its Biologics License Application for RP1 plus Opdivo in advanced melanoma.

    Source: